Corcept Therapeutics (CORT) reported Q1 earnings Monday of $0.17 per diluted share, down from $0.25 a year earlier.
Four analysts polled by FactSet expected $0.14.
Revenue for the quarter ended March 31 was $157.2 million, up from $146.8 million a year earlier.
Four analysts surveyed by FactSet expected $177.9 million.
The company reiterated its 2025 revenue outlook between $900 million and $950 million.
Four analysts polled by FactSet expect $905.4 million.
The company's shares were falling past 8% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.